```html

Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare, life‑threatening autoimmune disease characterized by inflammation of small‑ and medium‑size blood vessels (vasculitis) and the formation of granulomas—clusters of inflammatory cells—in the respiratory tract and kidneys. GPA belongs to the family of ANCA‑associated vasculitides (AAV).

• Incidence: Approximately 3 – 4 new cases per 1 million people each year in North America and Europe.<sup>[1]</sup>
• Prevalence: About 20 – 25 cases per 1 million individuals overall.<sup>[2]</sup>
• Gender: Slight male predominance (≈55 % male).
• Age: Bimodal peaks—most commonly diagnosed between ages 40–60, but can occur in children and the elderly.

The disease can affect virtually any organ system, but the classic “triad” involves the upper airway (sinusitis, nasal ulcers), lungs (cough, hemoptysis), and kidneys (glomerulonephritis).

Symptoms

Because GPA can involve many organs, symptoms vary widely. They often develop over weeks to months and may be mild at first.

Upper Respiratory Tract

• Persistent nasal congestion or discharge
• Recurrent sinusitis or sinus pain
• Ulcerated or crusted nasal septum (often “saddle‑nose” deformity after cartilage loss)
• Ear pain or hearing loss due to middle‑ear effusion
• Hard palate ulcers

Lower Respiratory Tract

• Dry cough
• Shortness of breath
• Chest pain, especially pleuritic
• Hemoptysis (coughing up blood)
• Frequent lung infections secondary to airway inflammation

Renal (Kidney) Involvement

• Hematuria (blood in urine)
• Proteinuria (protein in urine)
• Decreased urine output
• Swelling of the ankles or feet (edema)
• Rapid rise in serum creatinine—sign of acute kidney injury

General/Systemic Symptoms

• Fatigue and weakness
• Unexplained weight loss
• Fever or low‑grade chills
• Arthralgia (joint pain) without swelling
• Skin lesions: palpable purpura, necrotic ulcers, or livedo reticularis

Other Organ Manifestations

• Eye: scleritis, conjunctivitis, or orbital inflammation
• Nervous system: mononeuritis multiplex, peripheral neuropathy, or central nervous system involvement (rare)
• Heart: pericarditis, myocarditis
• Gastrointestinal: abdominal pain, melena (due to intestinal vasculitis)

Causes and Risk Factors

The exact trigger for GPA remains unknown, but current research points to a combination of genetic susceptibility, environmental exposures, and immune dysregulation.

Genetic Factors

• Strong association with HLA‑DPB1*04 and certain variants of the PR3 gene, which encodes proteinase‑3, the target of the most common ANCA (c‑ANCA).<sup>[3]</sup>

Environmental Triggers

• Silica dust exposure (miners, construction workers)
• Chronic nasal carriage of Staphylococcus aureus (linked to higher relapse rates).<sup>[4]</sup>
• Medication‑induced vasculitis (e.g., propylthiouracil, cocaine adulterated with levamisole) can mimic GPA.

Other Risk Factors

• Smoking – increases risk of lung involvement and relapse.
• History of other autoimmune diseases (e.g., rheumatoid arthritis) may slightly elevate risk.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, serologic testing, imaging, and tissue biopsy.

Laboratory Tests

• ANCA testing:
  • c‑ANCA (cytoplasmic) with anti‑proteinase‑3 (PR3) specificity – positive in ~80 % of generalized disease.
  • p‑ANCA (perinuclear) with anti‑myeloperoxidase (MPO) – seen in a minority of cases.
• Complete blood count (CBC) – may reveal anemia or leukocytosis.
• Renal panel – serum creatinine, blood urea nitrogen.
• Urinalysis – hematuria & proteinuria.
• Inflammatory markers – elevated ESR and CRP.

Imaging

• Chest X‑ray/CT scan: nodules, cavitary lesions, or diffuse infiltrates.
• Sinus CT: mucosal thickening, bony destruction.
• Renal ultrasound: helps evaluate kidney size & exclude obstruction.

Biopsy (Gold Standard)

Definitive diagnosis usually requires histopathologic confirmation of necrotizing granulomatous inflammation and vasculitis.

• Kidney biopsy – shows pauci‑immune necrotizing glomerulonephritis.
• Lung or nasal tissue – granulomas with necrosis, but not always present.

Classification Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria assign points for ANCA status, organ involvement, and histology; a score ≥5 classifies GPA with high specificity (≈96 %).<sup>[5]</sup>

Treatment Options

Therapy aims to induce remission quickly, then maintain it while minimizing drug toxicity.

Induction Therapy (Remission‑Inducing)

• Glucocorticoids: High‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone pulses (500–1000 mg/day for 3 days) until symptoms improve.
• Immunosuppressive agents:
  • Rituximab: 375 mg/m² weekly for 4 weeks (preferred for PR3‑ANCA and patients desiring fertility preservation) – FDA‑approved for GPA induction.<sup>[6]</sup>
  • Cyclophosphamide: Oral (2 mg/kg/day) or IV (15 mg/kg every 2‑3 weeks) – historically first‑line, but higher long‑term toxicity.
  • Methotrexate or Mycophenolate mofetil (MMF): Considered for non‑life‑threatening disease.

Maintenance Therapy (Prevent Relapse)

• Rituximab: 500 mg on days 0 and 14, then every 6 months.
• Azathioprine: 2 mg/kg/day for 12‑24 months.
• MMF: 1‑1.5 g twice daily (alternative if azathioprine not tolerated).
• Low‑dose glucocorticoids (≤5 mg prednisone) are usually tapered over 6–12 months.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole (TMP‑SMX): Prophylaxis against Pneumocystis jirovecii pneumonia (PCP) and may lower GPA relapse rates.<sup>[7]</sup>
• Bisphosphonates or calcium/vitamin D: Protect against glucocorticoid‑induced osteoporosis.
• Vaccinations: Inactivated vaccines (influenza, COVID‑19, pneumococcal) are recommended; live vaccines are avoided while on high‑dose immunosuppression.

Procedural Interventions

• Plasmapheresis – considered for severe renal disease or pulmonary hemorrhage (evidence mixed; may be used per physician judgment).
• Dialysis – for irreversible kidney failure.
• Sinus surgery – for chronic obstruction or structural damage after inflammation subsides.

Living with Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

Long‑term management focuses on medication adherence, monitoring, and lifestyle adjustments.

Medication Management

• Take all drugs exactly as prescribed; never stop steroids abruptly.
• Maintain a medication diary to track doses, side effects, and lab appointments.
• Set up reminders for routine blood work (CBC, liver/kidney function, ANCA levels) every 1‑3 months during induction, then every 3‑6 months during maintenance.

Monitoring & Follow‑Up

• Regular visits with a rheumatologist and, as needed, pulmonologist, nephrologist, or ENT specialist.
• Watch for early signs of relapse: new sinus symptoms, cough, hematuria, or unexplained fatigue.
• Urine dip‑stick testing at home can help detect early kidney involvement.

Lifestyle Tips

• Smoking cessation: Reduces lung damage and relapse risk.
• Balanced diet: Emphasize calcium‑rich foods, adequate protein, and low‑salt intake for kidney health.
• Physical activity: Low‑impact exercises (walking, swimming) improve stamina and bone health.
• Stress management: Mindfulness, yoga, or counseling can lessen fatigue and improve medication adherence.
• Stay hydrated—helps protect kidneys.

Emotional & Social Support

• Connect with patient‑advocacy groups such as the Vasculitis Foundation or the ANCA Association.
• Consider counseling to address anxiety or depression that may accompany chronic illness.

Prevention

Because GPA is autoimmune, primary prevention is not possible, but certain measures can lower the likelihood of disease flare‑ups or complications.

• Control exposure to silica dust and other inhaled irritants.
• Prompt treatment of chronic sinus infections and eradication of nasal S. aureus colonization (often with mupirocin nasal ointment).<sup>[4]</sup>
• Avoid medications known to trigger ANCA vasculitis (e.g., long‑term propylthiouracil) unless absolutely necessary.
• Maintain vaccinations and prophylactic antibiotics to reduce opportunistic infections while immunosuppressed.

Complications

If untreated or poorly controlled, GPA can lead to irreversible organ damage.

• Kidney failure: Up to 80 % of untreated patients develop end‑stage renal disease (ESRD).
• Permanent lung damage: Fibrosis, bronchiectasis, or recurrent pneumonias.
• Upper airway destruction: Saddle‑nose deformity, chronic sinusitis, or obstructive sleep apnea.
• Neuropathy: Mononeuritis multiplex causing weakness or sensory loss.
• Infections: Immunosuppression heightens risk for bacterial, viral, and fungal infections (including PCP).
• Medication toxicity: Cyclophosphamide can cause infertility, bladder toxicity, or secondary malignancies; long‑term steroids cause osteoporosis, diabetes, cataracts.
• Increased cardiovascular risk: Chronic inflammation accelerates atherosclerosis.

When to Seek Emergency Care

---

Sources: [1] Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” 2023.
[2] CDC. “Vasculitis Data and Statistics.” 2022.
[3] Jennette JC, et al. “Genetic susceptibility in ANCA‑associated vasculitis.” *Nat Rev Rheumatol*. 2021.
[4] de Prost N, et al. “Staphylococcus aureus colonization and relapse risk in GPA.” *Lancet Infect Dis*. 2020.
[5] ACR/EULAR Vasculitis Classification Working Group. “2022 Classification Criteria for GPA.” *Arthritis Rheumatol.* 2022.
[6] FDA. “Rituxan (rituximab) prescribing information.” 2023.
[7] Furuta S, et al. “TMP‑SMX prophylaxis reduces GPA relapse.” *Ann Rheum Dis*. 2018.

```